(R)-6-Hydroxywarfarin (BioDeep_00000172056)

   

human metabolite blood metabolite


代谢物信息卡片


4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one

化学式: C19H16O5 (324.0997686)
中文名称: 6-羟基华法林
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC(O)=C2
InChI: InChI=1S/C19H16O5/c1-11(20)9-14(12-5-3-2-4-6-12)17-18(22)15-10-13(21)7-8-16(15)24-19(17)23/h2-8,10,14,21-22H,9H2,1H3

描述信息

D006401 - Hematologic Agents > D000925 - Anticoagulants > D015110 - 4-Hydroxycoumarins

同义名列表

8 个代谢物同义名

4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; 4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one; 6-Hydroxywarfarin, (S)-isomer; 6-Hydroxywarfarin, (R)-isomer; (R)-6-Hydroxywarfarin; 6-hydroxy Warfarin; 6-Hydroxywarfarin; Warfarin-alcohol



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Darcy R Flora, Allan E Rettie, Richard C Brundage, Timothy S Tracy. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites. Journal of clinical pharmacology. 2017 03; 57(3):382-393. doi: 10.1002/jcph.813. [PMID: 27539372]
  • Steven Lane, Sameh Al-Zubiedi, Ellen Hatch, Ivan Matthews, Andrea L Jorgensen, Panos Deloukas, Ann K Daly, B Kevin Park, Leon Aarons, Kayode Ogungbenro, Farhad Kamali, Dyfrig Hughes, Munir Pirmohamed. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British journal of clinical pharmacology. 2012 Jan; 73(1):66-76. doi: 10.1111/j.1365-2125.2011.04051.x. [PMID: 21692828]
  • Drew R Jones, So-Young Kim, Michael Guderyon, Chul-Ho Yun, Jeffery H Moran, Grover P Miller. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chemical research in toxicology. 2010 May; 23(5):939-45. doi: 10.1021/tx1000283. [PMID: 20429590]
  • Grover P Miller, Drew R Jones, Shane Z Sullivan, Anna Mazur, Suzanne N Owen, Neil C Mitchell, Anna Radominska-Pandya, Jeffery H Moran. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chemical research in toxicology. 2009 Jul; 22(7):1239-45. doi: 10.1021/tx900031z. [PMID: 19408964]
  • Igor Locatelli, Vojko Kmetec, Ales Mrhar, Iztok Grabnar. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 Apr; 818(2):191-8. doi: 10.1016/j.jchromb.2004.12.024. [PMID: 15734158]
  • J X de Vries, E Schmitz-Kummer. Development of a method for the analysis of warfarin and metabolites in plasma and urine. American clinical laboratory. 1995 Jul; 14(7):20-1. doi: NULL. [PMID: 10155056]
  • R J Lewis, W F Trager, K K Chan, A Breckenridge, M Orme, M Roland, W Schary. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. The Journal of clinical investigation. 1974 Jun; 53(6):1607-17. doi: 10.1172/jci107711. [PMID: 4830225]